The trial may be double blinded, but they never said anything about not hearing stuff. Does anyone think Gil would go out on a limb like this without knowing the results?
better do it early. Should I risk cash I've set aside for the IRS? That is the question for me. What bothers me is I'm actually thinking about it.
"No surprise they wan't to see efficacy before spending more money on a late stage III trial."
Lets remember the agreement between ATHX and Pfizer.
From one my previous posts:
Could we be seeing a part of this milestone payment for completion of phase II ?
"Under the terms of the agreement, Athersys will receive an up-front cash payment of $6 million from Pfizer, as well as research funding and support during the initial phase of the collaboration. In addition, Athersys is also eligible to receive milestone payments of up to $105 million upon the successful achievement of certain development, regulatory and commercial milestones. Pfizer will have responsibility for development, regulatory and commercialization and will pay Athersys tiered royalties on worldwide commercial sales of MultiStem IBD products. Alternatively, in lieu of royalties and certain commercialization milestones, Athersys may elect to co-develop with Pfizer and the parties will share development and commercialization expenses and profits/losses on an agreed basis beginning at phase III clinical development."
Last part of the above:
", Athersys may elect to co-develop with Pfizer and the parties will share development and commercialization expenses and profits/losses on an agreed basis beginning at phase III clinical development."
Sounds to me that after phase II, and before phase III Athersys has a decision to make. So there may well be a milestone payment due at that time depending on their decision? Comments.?
That says a lot.
real time clock is still an hour behind. Had to wait over an hour for some in laws to celebrate their wedding anniversary yesterday because they forgot to set their clocks up, but they were in their 70's and 80's so they could be excused. LOL.
Wouldn't it be nice if their expansion was due to a collaboration with ATHX.
"Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized contract development and manufacturing organization, announced today that PCT has expanded both its Allendale, NJ and Mountain View, CA current Good Manufacturing Practice ("cGMP") facilities to significantly increase its engineering and process development laboratories, and controlled environment ("clean room") space available for client needs. Furthermore, the expansion in the Allendale, NJ facility features an ISO Class 6/1,000 clean room, enabling PCT to manufacture products intended for European distribution.
"The expansion of our facilities is well in line with the growing demand for PCT's contract development and manufacturing services," said Dr. Robert A. Preti, Chief Scientific Officer of NeoStem and President of PCT. "PCT has always prided itself on delivering excellent customer service and now we can offer our clients more capacity and options for solutions at our facilities to expedite the development and manufacture of their cell therapy products. The non-clean room expansion activities will both improve our capability to provide product development support, and importantly provide room for PCT's Engineering and Innovation Center to grow."
Obviously they expect growth in the Regenerative therapy field.
Once efficacy is proven in humans, depending on degree, it will go through the roof because everyone will want in. What really differentiates MultiStem vs other products is its procedure, its off the self availability, ease of use, and volume of product per donor. It will be a highly marketable product that could eventually, after proof of concept, be used easily by many doctors not just highly trained specialist, which will make it even more appealing to insurance companies It will be great for patients, investors, and insurance companies since it will save them billions in house health care cost, and cut time in hospital care environment, and hopefully greatly improve quality of life. Sounds too good to be true, lets pray that it is for all involved.
Have you tried to do an internet search for any follow ups on William and Denise Cunningham? I've tried but have been unable to find anything with an association to MutiStem, or even about stroke recovery. So, there has to be a concerted effort to suppress any details. I would think other people would at least have tried to do a follow up and if they have found anything would have posted something. But so far nothing that I have seen.
The following concern and a response from Ihub users:
expediter13 Member Level Wednesday, 03/05/14 08:47:22 AM
Re: loanranger post# 587
Post # of 610
Thus the 13th CC... I happen to be real in tune with what these guys are doing. I am a little worried about the lack of transparency from any patient (anywhere worldwide) on it helping them in any way. People usually can't keep their mouths shut. You would think somewhere someone would say something..
Although if you listen to Dr. GIL you will buy the stock, period... He wasn't like that for years, way more laid back and waiting for the science. They are positioned well. I just don't see how it could be possible for the company to put out all they have this past 3 months without having a great product ready to go and with "EFFICACY" up the yahoo...
and the response :
Seel Wednesday, 03/05/14 06:04:50 PM
Re: expediter13 post# 593
Post # of 610
expediter - though only a ph2, the study is randomized, doubled blind placebo controlled. It is not open label. We hear patient reports from open label trials. This is trial where patients contracted to high level of confidentiality which includes prohibition of any references to progress on internet and social media. If patient sick enough to require caregiver, caregiver often has to sign for same silence rules in order for patient to participate. It is most uncommon for these confidentiality contracts to be breached by trial participants.
Stocks don't get ahead of themselves as much as they get ahead of investors.
Not as risky as being short at $3.00 a month and a half ago.
That would be a fast track to revenue without giving the whole house away. And having a company like Takeda with all of their contacts, and influence certainly wouldn't hurt, and may greatly improve our chances and the all important time factor.
$ATHX price target as of today ..high 10.00 mean 8.67 low price is 7.00 per thomson/rueters .........
stocktwits 28 minutes ago
4 analyst covering. Nice.